|
[1]FINUCANE MM, STEVENS GA, COWAN MJ, et al.National, regional, and global trends in body-mass index since 1980:systematic analysis of health examination surveys and epidemiological studies with 960 countryyears and“9.1”million participants[J].Lancet, 2011, 377 (9765) :557-567.
|
|
[2]FAN JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 1) :11-17.
|
|
[3]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.
|
|
[4] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.
|
|
[5]NEWSOME PN, ALLISON ME, ANDREWS PA, et al.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis[J].Gut, 2012, 61 (4) :484-500.
|
|
[6]ALBELDAWI M, AGGARWAL A, MADHWAL S, et al.Cumulative risk of cardiovascular events after orthotopic liver transplantation[J].Liver Transpl, 2012, 18 (3) :370-375.
|
|
[7]AGRAWAL S, DARUWALA C.Metabolic syndrome and hepatic resection:improving outcome[J].HPB (Oxford) , 2011, 13 (12) :846-859.
|
|
[8]FAN JG, PENG YD.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary Pancreat Dis Int, 2007, 6 (6) :572-578.
|
|
[9]FAN JG, CAI XB, LI L, et al.Alcohol consumption and metabolic syndrome among Shanghai adults:A randomized multistage stratified cluster sampling investigation[J].World J Gastroenterol, 2008, 14 (15) :2418-2424.
|
|
[10]GUNJI T, MATSUHASHI N, SATO H, et al.Alcohol consumption is inversely correlated with insulin resistance, independent of metabolic syndrome factors and fatty liver diseases[J].J Clin Gastroenterol, 2011, 45 (9) :808-813.
|
|
[11]O’SHEA RS, DASARATHY S, McCULLOUGH AJ.Alcoholic liver disease.AASLD practice guideline[J].Hepatology, 2010, 51 (1) :307-328.
|
|
[12]JIA QY.Current situation of treatment of alcoholic liver disease[J].Jllin J Tradit Chin Med, 2012, 32 (5) :536-537. (in Chinese) 贾秋颖.酒精性肝病治疗现状[J].吉林中医药, 2012, 32 (5) :536-537.
|
|
[13]KIM JH, KIM SY, JUNG ES, et al.Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic fatty liver patients[J].Digestion, 2011, 84 (2) :149-155.
|
|
[14]BUGIANESI E, SALAMONE F, NEGRO F.The interaction of metabolic factors with HCV infection:does it matter?[J].J Hepatol, 2012, 56 (Suppl 1) :s56-s65.
|
|
[15]ADINOLFI LE, RESTIVO L, ZAMPINO R, et al.Chronic HCV infection is a risk of atherosclerosis.Role of HCV and HCV-related steatosis[J].Atherosclerosis, 2012, 221 (2) :496-502.
|
|
[16]FAN JG, CHITTURI S.Hepatitis B and fatty liver:causal or coincidental?[J].J Gastroenterol Hepatol, 2008, 23 (5) :779-782.
|
|
[17]HSU CS, LIU CH, WANG CC, et al.Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J].J Viral Hepat, 2012, 19 (2) :e48-e57.
|
|
[18]WONG VW, WONG GL, CHU WC, et al.Hepatitis B virus infection and fatty liver in the general population[J].J Hepatol, 2012, 56 (3) :533-540.
|
|
[19]ZHANG Z, PAN Q, DUAN XY, et al.Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J].J Gastroenterol Hepatol, 2012, 27 (12) :1858-1864.
|
|
[20]BORENA W, STROHMAIER S, LUKANOVA A, et al.Metabolic risk factors and primary liver cancer in a prospective study of 578, 700 adults[J].Int J Cancer, 2012, 131 (1) :193-200.
|
|
[21]WELZEL TM, GRAUBARD BI, ZEUZEM S, et al.Metabolic syndrome increases the risk of primary liver cancer in the United States:a study in the SEER-Medicare database[J].Hepatology, 2011, 54 (2) :463-471.
|
|
[22] SHI JP, LU L, QIAN JC, et al.Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B[J].Chin J Hepatol, 2012, 20 (4) :285-288. (in Chinese) 施军平, 陆璐, 钱建成, 等.肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J].中华肝脏病杂志, 2012, 20 (4) :285-288.
|
|
[23]FUNG J, YUEN MF, LAI CL.The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection:fact or fiction?[J].Dig Dis Sci, 2013, 58 (1) :20-22.
|
|
[24]FAN JG, SAIBARA T, CHITTURI S, et al.What are the risk factors and settings of nonalcoholic fatty liver disease in Asia-Pacific[J].J Gastroenterol Hepatol, 2007, 22 (6) :794-800.
|
|
[25]DUAN XY, QIAO L, FAN JG.Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int, 2012, 11 (1) :18-27.
|
|
[26]FAN JG, FARRELL GC;Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma.Prevention of hepatocellular carcinoma in non-viral related liver diseases[J].J Gastroenterol Hepatol, 2009, 24 (5) :712-719.
|
|
[27] Expert Committee of Fatty Liver Disease, Chinese Medical Doctor Association.Expert recommendations for standardized management of fatty liver disease[J].J Clin Hepatol, 2013, 16 (3) :207-209. (in Chinese) 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].实用肝脏病杂志, 2013, 16 (3) :207-209.
|
DownLoad: